89bio Reports Second Quarter 2024 Financial Results and Corporate Updates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
89bio Inc. (ETNB) PT Lowered to $12 at RBC Capital
August 6, 2024 6:41 AM EDTRBC Capital analyst Brian Abrahams lowered the price target on 89bio Inc. (NASDAQ: ETNB) to $12.00 (from $13.00) while maintaining a Sector Perform rating.
The analyst comments "Both ph.III studies in MASH have been initiated and are enrolling. While we like pegoza's likely role... More
